Nazli G.Rahim Ph.D.

Associate

硅谷 + 1.650.687.4198

联系：

Share

Nazli Rahim's practice includes the preparation and prosecution of domestic and foreign patent applications in the fields of biotechnology, immunology, oncology, cell biology, and pharmaceuticals. She also has experience in conducting IP due diligence evaluations, patentability analysis, and freedom to operate analysis.

Nazli has drafted and prosecuted patent applications directed to CRISPR gene editing, antibody therapeutics, enzyme replacement therapies, CAR-T cell therapies, drug formulations, cancer therapeutics, and next-generation sequencing.

Prior to joining Jones Day, Nazli obtained her Ph.D. in genetics at Caltech, where she studied the molecular mechanisms underlying proteolysis. She has more than 10 years of industry experience and has conducted research at the European Molecular Biology Laboratory, the Cancer Research Center of Lyon, The Scripps Research Institute, and Genentech.

经验

  • Centrillion Technologies develops patent portfolios related to systems and methods for fabricating high resolution oligonucleotide arraysJones Day is representing Centrillion Technologies, Inc. in counseling and development of global patent portfolios related to systems and methods for fabricating high resolution oligonucleotide arrays, including their applications in sequencing and diagnosis.
  • Alamar Biosciences develops global patent portfolios related to biopsy platform involving Next Generation Sequencing (NGS)Jones Day is assisting Alamar Biosciences, Inc. with counseling and development of global patent portfolios related to a highly sensitive proteomic liquid biopsy platform involving Next Generation Sequencing (NGS).
  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.
  • ToolGen obtains ex parte PTAB appeal victory reversing examiner's rejections in CRISPR patent applicationOn June 22, 2020, Jones Day obtained a decision on behalf of ToolGen, Inc. at the United States Patent Trial and Appeal Board ("PTAB") reversing all of the examiner's obviousness rejections of the claims in ToolGen's U.S. Patent Application No. 14/685,510 (Appeal No. 2019-001990).
  • Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 millionJones Day advised Royalty Pharma, the industry leader in acquiring pharmaceutical royalties, in its $260 million acquisition of the royalty interest held by Arteaus Therapeutics, LLC on future global net sales of Eli Lilly and Company’s EMGALITY® (galcanezumab), an anti-CGRP antibody for the prevention of migraine.
    •

    December 2019 Commentary

    Artificial Intelligence and the Biopharmaceutical Industry: What's Next?

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice